Switzerland-based Roivant hosted an Investor Day in New York City today, highlighting its leadership with key pipeline ...

Dutch privately-held company ProteoNic, a provider of premium vector technology for biopharmaceutical and viral vector production, today announced that its proprietary 2G UNic technology has been ...

As a physical embodiment of the ambition of Accord Healthcare to establish itself as a leader in the global health landscape, ...

Swiss clinical-stage biotech AC Immune today announced positive interim safety and efficacy results from the Phase II VacSYn ...

Swiss pharma giant Roche (SIX: ROG) has announced positive data from the Phase III lidERA Breast Cancer study of giredestrant ...

PsiThera has closed a $47.5 million series A round to advance oral therapies for immune and inflammatory diseases. The company also named former Seres Therapeutics (Nasdaq: MCRB) chief executive Eric ...

The bipolar disorder market across the USA, Europe, and Japan is forecast to rise from $5.6 billion in 2024 to $9.4 billion ...

German biotech Disco Pharmaceuticals has appointed Mark Manfredi as chief executive and closed a 36 million euro ($39 million ...

For decades, the generics industry has been dedicated to supporting the financial sustainability of health systems. By ...

Chinese regulator the National Medical Products Administration (NMPA) has approved two innovative medicines for rare hematologic diseases: Qfitlia (fitusiran) for hemophilia and Cablivi (caplacizumab) ...

Hong Kong-based Ascletis Pharma has announced that its New Drug Application (NDA) for denifanstat (ASC40), a first-in-class, ...

Diakonos Oncology has received more than $7 million from the Cancer Prevention and Research Institute of Texas to support a ...